About this episode

Experts discuss the role of GPRC5D-targeted therapy in the treatment of multiple myeloma.

Targeted therapies are becoming more common treatment options for patients with multiple myeloma. Specifically, there have been emerging clinical data on GPRC5D-directed bispecific antibodies for patients with relapsed and refractory disease. In this podcast, 2 experts in the field discuss how they are using GPRC5D-directed therapies in their practice, including treatment planning, patient selection, adverse event management, and how new combination strategies may affect practice.

More episodes of Decera Clinical Education Oncology Podcast

• What Oncology Pharmacists Need to Know About Targeting BCMA in Early Relapsed/Refractory Myeloma · July 13, 2026 · 29 min
• Incorporating AKT1 and PIK3CA Pathway Testing and Targeted Therapies in the Management of Advanced Endocrine-Resistant Breast Cancer · June 30, 2026 · 24 min
• Personalizing EGFR Mutation–Positive NSCLC Care: Strategies for the Advanced Practice Provider · June 22, 2026 · 27 min

Explore listener stats, chart rankings, contacts and more on the Decera Clinical Education Oncology Podcast podcast page.